## VPA10491/010/001

## Aqupharm 1 (9 mg/ml) solution for injection/infusion

| Variation            | Summary   | Date     |
|----------------------|---|----------|
| Vet - G.I.18         | VRA-S - Vet - G.I.18 Vet - G.I.18 - One-off alignment of the product information with version 9.0* of the QRD templates i.e. major update of the QRD templates in accordance with Regulation (EU) 2019/6, for veterinary medicinal products authorised in accordance with Directive 2001/82/EC or Regulation (EC) No 726/2004   | 06/10/25 |
| Vet - F.II.e.5 a)    | VRA-R - Vet - F.II.e.5 a) Vet - F.II.e.5 a) - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack outside the range of the currently approved pack sizes   | 06/10/25 |
| Vet - B21            | VNRA - Vet - B21 - Replacement or addition of a secondary packaging site of a finished product - B21 Changes to the quality part of the dossier: Replacement or addition of a secondary packaging site of a finished product  | 16/06/23 |
| Vet - F.III.1 a) 1.  | VRA-R - Vet - F.III.1 a) 1 a) European Pharmacopoeial Certificate of Suitability to the relevant Ph. Eur. Monograph.  1. New certificate for a non-sterile active substance that is to be used in a sterile medicinal product, where water is used in the last steps of the synthesis and the material is not claimed to be endotoxin free - F.III.1 a) 1. Quality Changes - CEP/TSE/MONOGRAPHS - Submission of a new or updated Ph. Eur. certificate of suitability or deletion of Ph. Eur. certificate of suitability: -For an active substance -For a starting material/reagent/intermediate used in the manufacturing process of the active substance -For an excipient European Pharmacopoeial Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate for a non-sterile active substance that is to be used in a sterile medicinal product, where water is used in the last steps of the synthesis and the material is not claimed to be endotoxin free | 09/06/23 |
| Vet - F.II.b.3 h)    | VRA-R - Vet - F.II.b.3 h) - h) Change in the holding time of an intermediate or bulk product (if applicable) - F.II.b.3 h) Quality Changes - Finished Product -Manufacture - Change in the manufacturing process of the finished product, including an intermediate used in the manufacture of the finished product - Change in the holding time of an intermediate or bulk product (if applicable)   | 09/06/23 |
| Vet - F.II.e.1 a) 2. | VRA-S - Vet - F.II.e.1 a) 2 a) Qualitative and quantitative composition 2. Sterile medicinal products and biological/immunological medicinal products F.II.e.1 a) 2.  | 09/06/23 |

| Vet - F.II.d.1 a) | VRA-S - Vet - F.II.d.1 a) - a) Change outside the approved specifications limits range - F.II.d.1 a) Quality Changes - Finished Product - Control of finished product - Change in the specification parameters and/or limits of the finished product - Change outside the approved specifications limits range   | 09/06/23 |
|-------------------|--|----------|
| Vet - F.II.d.2 b) | VRA-R - Vet - F.II.d.2 b) - b) Other changes to a test procedure (including replacement or addition) - F.II.d.2 b) Quality Changes - Finished Product - Control of finished product - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)  | 09/06/23 |
| Vet - F.II.d.2 a) | VRA-S - Vet - F.II.d.2 a) - a) Substantial change to, or replacement of, a biological/immunological/immunochemical test method or a method using a biological reagent or replacement of a biological reference preparation not covered by an approved protocol - F.II.d.2 a) Quality Changes - Finished Product -Control of finished product - Change in test procedure for the finished product - Substantial change to, or replacement of, a biological/immunological/immunochemical test method or a method using a biological reagent or replacement of a biological reference preparation not covered by an approved protocol | 09/06/23 |
| Vet - F.II.b.5 z) | VRA-R - Vet - F.II.b.5 z) - z) Other changes under this code level e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021 - F.II.b.5 z) Quality Changes - Finished Product -Manufacture - Change to in-process tests or limits applied during the manufacture of the finished product - Other changes under this code level, e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021  | 09/06/23 |
| Vet - F.II.b.5 z) | VRA-R - Vet - F.II.b.5 z) - z) Other changes under this code level e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021 - F.II.b.5 z) Quality Changes - Finished Product - Manufacture - Change to in-process tests or limits applied during the manufacture of the finished product - Other changes under this code level, e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021   | 09/06/23 |
| Vet - F.II.b.4 z) | VRA-R - Vet - F.II.b.4 z) - z) Other changes under this code level e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021 - F.II.b.4 z) Quality Changes - Finished Product -Manufacture - Change in the batch size (including batch size ranges) of the finished product - Other changes under this code level, e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021   | 09/06/23 |
| Vet - F.II.a.3 z) | VRA-R - Vet - F.II.a.3 z) - z) Other changes under this code level e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021 - F.II.a.3 a) Quality Changes - Finished Product - Description and composition - Changes in the composition (excipients) of the finished product - Other changes under this code level, e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021   | 09/06/23 |

|                      | VRA-R - Vet - F.II.a.3 z) - z) Other changes under this code   |          |
|----------------------|--|----------|
| Vet - F.II.a.3 z)    | level e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021 - F.II.a.3 a) Quality Changes - Finished Product - Description and composition - Changes in the composition (excipients) of the finished product - Other changes under this code level, e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021  | 09/06/23 |
| Vet - F.II.b.3 i)    | VRA-R - Vet - F.II.b.3 i) - i) Minor change in the manufacturing process of a sterile finished product after the primary packaging step - F.II.b.3 i) Quality Changes - Finished Product - Manufacture - Change in the manufacturing process of the finished product, including an intermediate used in the manufacture of the finished product - Minor change in the manufacturing process of a sterile finished product after the primary packaging step   | 09/06/23 |
| Vet - F.II.b.3 a)    | VRA-R - Vet - F.II.b.3 a) - a) Minor change in the manufacturing process - F.II.b.3 a) Quality Changes - Finished Product -Manufacture - Change in the manufacturing process of the finished product, including an intermediate used in the manufacture of the finished product - Minor change in the manufacturing process  | 09/06/23 |
| Vet - F.II.b.3 a)    | VRA-R - Vet - F.II.b.3 a) - a) Minor change in the manufacturing process - F.II.b.3 a) Quality Changes - Finished Product -Manufacture - Change in the manufacturing process of the finished product, including an intermediate used in the manufacture of the finished product - Minor change in the manufacturing process  | 09/06/23 |
| Vet - F.II.b.1 d)    | VRA-R - Vet - F.II.b.1 d) - d) Site where any manufacturing operation(s) take place, except batch release, batch control, and secondary packaging, for sterile veterianry medicinal products (including those that are aseptically manufactured) excluding biological/ immunological veterinary medicinal products - F.II.b.1 d) Quality Changes - Finished Product - Manufacture - Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - Site where any manufacturing operation(s) take place, except batch release, batch control, and secondary packaging, for sterile veterianry medicinal products (including those that are aseptically manufactured) excluding biological/ immunological veterinary medicinal products | 09/06/23 |
| Vet - F.II.b.2 b) z. | VRA-R - Vet - F.II.b.2 b) z b) Replacement or addition of a manufacturer responsible for importation and/or batch release z. Other changes under this code level, e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021 - F.II.b.2 b) z. Quality Changes - Finished Product -Manufacture - Change to importer, batch release arrangements and quality control testing of the finished product - Replacement or addition of a manufacturer responsible for importation and/or batch release - Other changes under this code level, e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021  | 09/06/23 |

| Vet - F.II.b.2 a) z. | VRA-R - Vet - F.II.b.2 a) z a) Replacement or addition of a site where batch control/testing takes place z. Other changes under this code level, e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021 - F.II.b.2 a) z. Quality Changes - Finished Product -Manufacture - Change to importer, batch release arrangements and quality control testing of the finished product - Replacement or addition of a site where batch control/testing takes place - Other changes under this code level, e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021  | 09/06/23 |
|----------------------|--|----------|
| Vet - F.II.b.1 d)    | VRA-R - Vet - F.II.b.1 d) - d) Site where any manufacturing operation(s) take place, except batch release, batch control, and secondary packaging, for sterile veterianry medicinal products (including those that are aseptically manufactured) excluding biological/ immunological veterinary medicinal products - F.II.b.1 d) Quality Changes - Finished Product - Manufacture - Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - Site where any manufacturing operation(s) take place, except batch release, batch control, and secondary packaging, for sterile veterianry medicinal products (including those that are aseptically manufactured) excluding biological/ immunological veterinary medicinal products | 09/06/23 |
| Vet - C6             | VNRA - Vet - C6 - Introduction of a summary of the PSMF or changes to the summary of the PSMF not already covered elsewhere in the Annex to Regulation (EU) 2021/17 - C6 Changes to the safety, efficacy and pharmacovigilance part of the dossier: Introduction of a summary of the PSMF or changes to the summary of the PSMF not already covered elsewhere in the Annex to Regulation (EU) 2021/17  | 27/03/23 |
| Vet - C1             | VNRA - Vet - C1 - Change(s) in the name or address or contact details of a qualified person for pharmacovigilance (QPPV) - C1 Changes to the safety, efficacy and pharmacovigilance part of the dossier: Change(s) in the name or address or contact details of a qualified person for pharmacovigilance (QPPV)  | 27/03/23 |